Double-blind placebo-controlled trial of the effect of omalizumab on basophils in chronic urticaria patients.

Lukas JoergT Pecaric-PetkovicS ReichenbachM CoslovskyO StalderW PichlerO Hausmann

Published in: Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (2017)

We demonstrated a rapid reduction of FcεRI receptor density on basophils following treatment with omalizumab. Because CU-BAT using well-characterized, omalizumab-naïve donor basophils did not change during the treatment phase, autoreactive serum factors seem to remain unaltered. This points towards a cellular effect of omalizumab on basophils. To predict the omalizumab response time and to monitor disease, FcεRI density and CU-BAT might be promising cellular-based assays.

Keyphrases

double blind
end stage renal disease
ejection fraction
chronic kidney disease
prognostic factors
peritoneal dialysis
patient reported outcomes
smoking cessation
metal organic framework
aqueous solution
quantum dots
patient reported